secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0001213900-23-019022
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron Q4 net loss $4.5M, FY 2022 loss $18.8M; cash $19.6M, runway into H1 2024
--------------------------------------------------------------------------------

- Q4 2022 net loss $4.5M ($0.21/share) vs $4.1M; full year loss $18.8M ($0.90/share) vs $17.0M.
- Revenue Q4 $0.1M, full year $1.2M (flat vs $1.3M); clinical trial revenue up 29% to $0.9M.
- Cash and short-term investments $19.6M at Dec 31, 2022, down from $35.0M; funds operations into H1 2024.
- Completed enrollment in Phase 2a Alzheimer's trial (CLEAR MIND, 48 patients); topline results expected early 2024.
- Initiated Phase 2 Aging-Related Frailty trial in Japan; first patient randomization expected Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023019022/0001213900-23-019022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023019022/ea175011-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-019022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer